Multiple Myeloma (MM)Lenalidomide S.K. is indicated for the treatment of multiple myeloma.
Myelodysplastic Syndromes Lenalidomide S.K. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Lenalidomide S.K. 7.5 mg is not indicated for treatment in MDS.
Mantle Cell Lymphoma Lenalidomide S.K. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).
Follicular lymphoma Lenalidomide S.K. in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.
**Disclaimer:
The images and designs presented on this website are for illustrative purposes only. Actual products may differ from those shown, including variations in color, packaging design, wording, or other visual features. The company assumes no responsibility for any such discrepancies and does not undertake to update the website to reflect changes in the actual product.
*** Disclaimer
The information provided herein is not intended as medical advice and must not be relied upon for diagnosis, treatment, or the provision of medical care. It does not replace the official prescribing/patient leaflet or consultation with a qualified healthcare professional. Before any use, always review the official physician/patient leaflet and consult a licensed physician. The company assumes no responsibility or liability for any reliance placed on the information presented on this page.
